Risk Factors and Attack Rates of Seasonal Influenza Infection: Results of the Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) Seroepidemiologic Cohort Study.
Adolescent
Adult
Aged
Antibody Formation
/ immunology
Child
Child, Preschool
Cohort Studies
Female
Hemagglutination Inhibition Tests
Humans
Infant
Infant, Newborn
Influenza A Virus, H3N2 Subtype
/ immunology
Influenza Vaccines
/ immunology
Influenza, Human
/ epidemiology
Male
Middle Aged
Neuraminidase
/ immunology
New Zealand
/ epidemiology
Risk Factors
Seasons
Seroepidemiologic Studies
Young Adult
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
09 01 2019
09 01 2019
Historique:
received:
04
04
2018
accepted:
12
07
2018
pubmed:
18
7
2018
medline:
13
11
2019
entrez:
18
7
2018
Statut:
ppublish
Résumé
Understanding the attack rate of influenza infection and the proportion who become ill by risk group is key to implementing prevention measures. While population-based studies of antihemagglutinin antibody responses have been described previously, studies examining both antihemagglutinin and antineuraminidase antibodies are lacking. In 2015, we conducted a seroepidemiologic cohort study of individuals randomly selected from a population in New Zealand. We tested paired sera for hemagglutination inhibition (HAI) or neuraminidase inhibition (NAI) titers for seroconversion. We followed participants weekly and performed influenza polymerase chain reaction (PCR) for those reporting influenza-like illness (ILI). Influenza infection (either HAI or NAI seroconversion) was found in 321 (35% [95% confidence interval, 32%-38%]) of 911 unvaccinated participants, of whom 100 (31%) seroconverted to NAI alone. Young children and Pacific peoples experienced the highest influenza infection attack rates, but overall only a quarter of all infected reported influenza PCR-confirmed ILI, and one-quarter of these sought medical attention. Seroconversion to NAI alone was higher among children aged <5 years vs those aged ≥5 years (14% vs 4%; P < .001) and among those with influenza B vs A(H3N2) virus infections (7% vs 0.3%; P < .001). Measurement of antineuraminidase antibodies in addition to antihemagglutinin antibodies may be important in capturing the true influenza infection rates.
Sections du résumé
Background
Understanding the attack rate of influenza infection and the proportion who become ill by risk group is key to implementing prevention measures. While population-based studies of antihemagglutinin antibody responses have been described previously, studies examining both antihemagglutinin and antineuraminidase antibodies are lacking.
Methods
In 2015, we conducted a seroepidemiologic cohort study of individuals randomly selected from a population in New Zealand. We tested paired sera for hemagglutination inhibition (HAI) or neuraminidase inhibition (NAI) titers for seroconversion. We followed participants weekly and performed influenza polymerase chain reaction (PCR) for those reporting influenza-like illness (ILI).
Results
Influenza infection (either HAI or NAI seroconversion) was found in 321 (35% [95% confidence interval, 32%-38%]) of 911 unvaccinated participants, of whom 100 (31%) seroconverted to NAI alone. Young children and Pacific peoples experienced the highest influenza infection attack rates, but overall only a quarter of all infected reported influenza PCR-confirmed ILI, and one-quarter of these sought medical attention. Seroconversion to NAI alone was higher among children aged <5 years vs those aged ≥5 years (14% vs 4%; P < .001) and among those with influenza B vs A(H3N2) virus infections (7% vs 0.3%; P < .001).
Conclusions
Measurement of antineuraminidase antibodies in addition to antihemagglutinin antibodies may be important in capturing the true influenza infection rates.
Identifiants
pubmed: 30016464
pii: 5054657
doi: 10.1093/infdis/jiy443
pmc: PMC9006182
mid: NIHMS1793293
doi:
Substances chimiques
Influenza Vaccines
0
Neuraminidase
EC 3.2.1.18
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
347-357Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000480
Pays : United States
Investigateurs
Kathryn Haven
(K)
Bhamita Chand
(B)
Pamela Muponisi
(P)
Debbie Aley
(D)
Claire Sherring
(C)
Miriam Rea
(M)
Judith Barry
(J)
Tracey Bushell
(T)
Julianne Brewer
(J)
Catherine McClymont
(C)
Shona Chamberlin
(S)
Reniza Ongcoy
(R)
Kirstin Davey
(K)
Emilina Jasmat
(E)
Maree Dickson
(M)
Annette Western
(A)
Olive Lai
(O)
Sheila Fowlie
(S)
Faasoa Aupa'au
(F)
Louise Robertson
(L)
Pam Kawakami
(P)
Susan Walker
(S)
Robyn Madge
(R)
Amanda des Barres
(AD)
Helen Qiao
(H)
Fifi Tse
(F)
Mahtab Zibaei
(M)
Tirzah Korrapadu
(T)
Louise Optland
(L)
Cecilia Dela Cruz
(CD)
Commentaires et corrections
Type : CommentIn
Références
Nat Commun. 2013;4:1418
pubmed: 23361009
Epidemiol Rev. 1994;16(2):351-73
pubmed: 7713184
Epidemiology. 2015 Nov;26(6):862-72
pubmed: 26133025
Lancet. 2010 Mar 27;375(9720):1100-8
pubmed: 20096450
Am J Epidemiol. 2012 May 15;175(10):1062-74
pubmed: 22411862
Am J Hyg. 1953 Jul;58(1):16-30
pubmed: 13065268
Influenza Other Respir Viruses. 2013 Sep;7(5):872-86
pubmed: 23331969
Curr Top Microbiol Immunol. 2015;386:275-99
pubmed: 25033754
J Infect Dis. 1977 Dec;136 Suppl:S415-24
pubmed: 606765
PLoS One. 2010 Oct 14;5(10):e13211
pubmed: 20976224
J Infect Dis. 2013 Mar 15;207(6):974-81
pubmed: 23307936
Vaccine. 2015 Aug 7;33(33):4087-92
pubmed: 26143611
PLoS Pathog. 2012;8(12):e1003061
pubmed: 23271967
J Infect Dis. 2010 Dec 1;202(11):1634-8
pubmed: 20979454
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
Influenza Other Respir Viruses. 2015 Jul;9(4):179-90
pubmed: 25912617
J Clin Microbiol. 2011 Jul;49(7):2614-9
pubmed: 21593260
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2013 May;56(10):1363-9
pubmed: 23413420
Influenza Other Respir Viruses. 2010 Sep;4(5):249-58
pubmed: 20716156
Lancet. 1999 Oct 9;354(9186):1277-82
pubmed: 10520648
Am J Epidemiol. 1975 Dec;102(6):553-63
pubmed: 1202957
Nature. 2012 Mar 25;484(7395):519-23
pubmed: 22446628
N Engl J Med. 1972 Jun 22;286(25):1329-32
pubmed: 5027388
Am J Epidemiol. 1985 Jun;121(6):811-22
pubmed: 4014174
Lancet. 1973 Mar 24;1(7804):623-5
pubmed: 4121842
mBio. 2016 Apr 19;7(2):e00417-16
pubmed: 27094330
Influenza Other Respir Viruses. 2009 Sep;3(5):233-40
pubmed: 21462400
Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83
pubmed: 21692672
J Infect Dis. 1977 Apr;135(4):499-506
pubmed: 856917
Epidemiology. 2010 Sep;21(5):726-8
pubmed: 20585253
Am J Epidemiol. 1966 May;83(3):436-54
pubmed: 4286697
Clin Infect Dis. 2010 Aug 1;51(3):274-9
pubmed: 20575664
Lancet Respir Med. 2014 Jun;2(6):445-54
pubmed: 24717637
Expert Rev Vaccines. 2011 Dec;10(12):1683-95
pubmed: 22085172